Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819705 | 1.00 | KDM4E (0.48) | KDM4ELMNANR1H4ALDH1A1APP | |
| SCHEMBL6819709 | 1.00 | KDM4E (0.48) | KDM4ELMNANR1H4ALDH1A1APP | |
| SCHEMBL6820102 | 0.91 | KDM4E (0.48) | KDM4ELMNANR1H4ALDH1A1APP | |
| SCHEMBL6820096 | 0.91 | KDM4E (0.48) | KDM4ELMNANR1H4ALDH1A1APP | |
| SCHEMBL6820100 | 0.91 | KDM4E (0.48) | KDM4ELMNANR1H4ALDH1A1APP | |
| SCHEMBL4878533 | 0.85 | APP (0.60) | KDM4ELMNAALDH1A1APPMAPT | |
| SCHEMBL2138448 | 0.85 | KDM4E (0.55) | KDM4ELMNAALDH1A1APPL3MBTL1 | |
| SCHEMBL811245 | 0.85 | KDM4E (0.55) | KDM4ELMNAALDH1A1APPL3MBTL1 | |
| SCHEMBL2138446 | 0.85 | KDM4E (0.55) | KDM4ELMNAALDH1A1APPL3MBTL1 | |
| SCHEMBL4878539 | 0.85 | APP (0.60) | KDM4ELMNAALDH1A1APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-1237856-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040172-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | KDM4E 3520/4885LMNA 1312/4885NR1H4 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.